RxDoctor Payments DataLook up a doctor →

Andrew Fields, APRN

Family · Columbia, SCNPI 1295784999

Payments from drug & device makers

$11,910in general payments, 2019–2025

Across 675 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • AbbVie$1K
  • Novo Nordisk$941
  • Medtronic$938
  • Bayer$791
  • plus $5K from 45 others

What the payments were for

  • Food & beverage$11,885100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,910 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$48,098
Medicare patients
128
Services billed
1,036

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol61$66,696
OzempicSemaglutide40$41,392
JardianceEmpagliflozin52$40,633
EliquisApixaban39$39,324
MounjaroTirzepatide21$37,888
TrulicityDulaglutide12$23,243
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$22,717
Breztri AerosphereBudesonide/Glycopyr/Formoterol31$22,709
XareltoRivaroxaban13$15,140
LinzessLinaclotide20$12,975
MyrbetriqMirabegron23$11,309
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$7,244
Atomoxetine Hcl13$2,967
Atorvastatin Calcium230$2,349
Omeprazole139$2,273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$1,368$89,40692 claims
Lilly USA, LLCMounjaro, Trulicity$1,306$61,13133 claims
Novo NordiskOzempic$941$41,39240 claims
Boehringer IngelheimJardiance$419$40,63352 claims
PfizerEliquis$451$39,32439 claims
GSKTrelegy Ellipta$32$22,71724 claims
Johnson & JohnsonXarelto$37$15,14013 claims
AbbVieLinzess$1,247$12,97520 claims
Astellas Pharma US IncMyrbetriq$30$11,30923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.

Other family in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →